Helix BioPharma Corp. (HBPCF)
| Market Cap | 29.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.78M |
| Shares Out | n/a |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Average Volume | 1 |
| Open | 0.6600 |
| Previous Close | 0.4500 |
| Day's Range | 0.4500 - 0.6600 |
| 52-Week Range | 0.1400 - 0.9200 |
| Beta | -0.85 |
| RSI | 48.16 |
| Earnings Date | Jun 13, 2025 |
About Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It... [Read more]
News
Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan
April 10, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Urgent Solutions to Fight Cancer: How Helix BioPharma is Tackling the Toughest Challenges
Helix BioPharma is a clinical-stage biopharmaceutical company aiming to turn scientific breakthroughs into real-world solutions for some of the most difficult-to-treat cancers.
Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services
April 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a n...
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
March 26, 2025 - (Toronto, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a nea...
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025
March 18, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain
March 11, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Helix Biopharma Corp. Expands Leadership Team with World-Class Oncology and Scientific Experts
March 6, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near...
Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing
March 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“ Helix ” or the “ Company ”), a clinical-stage oncology company shaping a ne...
Helix BioPharma Corp. Extends Date of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing
February 24, 2025 - (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Helix Biopharma appoints James Murphy as CFO
Helix BioPharma appoints James Murphy as Chief Financial Officer, previously a consultant with Danforth Advisors.
Helix Biopharma signs LOI to acquire Laevoroc Group's oncology assets
Helix Biopharma announces CFO resignation
Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.
VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp. ("Helix" or the "Compa...
Helix Biopharma Corp. Closes Private Placement
RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members
RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription
RICHMOND, ON / ACCESSWIRE / April 13, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-o...
Helix Biopharma Corp. Announces Management and Board Changes
RICHMOND HILL, ON / ACCESSWIRE / March 22, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results
RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix Biopharma Corp. Announces Unexpected Passing of Interim CEO and Chairman of the Board
RICHMOND HILL, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company") today announces, with great sadness, the sudden passing of its Interim Chief Executive Offi...
CORRECTION: Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period
(This release corrects the release that was posted earlier on March 11, 2022 due to the incorrect company logo being added. This release adds the corrected logo) RICHMOND HILL, ON / ACCESSWIRE / March...
Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period
RICHMOND HILL, ON / ACCESSWIRE / March 11, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix BioPharma Corp. Provides Corporate Update
RICHMOND HILL, ON / ACCESSWIRE / December 31, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and...
Helix BioPharma Corp. Extends Period to Exercise Warrants
RICHMOND HILL, ON / ACCESSWIRE / December 14, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the preve...
Helix Biopharma Corp. Announces Fiscal 2021 Year-End Results
RICHMOND HILL, ON / ACCESSWIRE / December 9, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field...
Helix BioPharma Corp. Provides Third Bi-Weekly MCTO Status Update
RICHMOND HILL, ON / ACCESSWIRE / November 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and...